Literature DB >> 23087177

PD-1 is a novel regulator of human B-cell activation.

Marie-Laure Thibult1, Emilie Mamessier, Julie Gertner-Dardenne, Sonia Pastor, Sylvaine Just-Landi, Luc Xerri, Bruno Chetaille, Daniel Olive.   

Abstract

The outcome of the adaptive immune response is determined by the integration of both positive and negative signals, respectively, induced upon the triggering of co-signaling receptors. One of them, programmed cell death 1 (PDCD1/PD-1) has largely been shown to be involved in the negative regulation of T-cell activation. However, PD-1 is also expressed on human B cells, and its role(s) in the process of human B-cell activation remains uncertain thus far. In this study, we describe the expression of PD-1 on the major human B-cells subsets isolated from peripheral blood and lymph nodes. We showed that PD-1 was expressed on naive B cells, was differentially expressed on peripheral IgM memory as compared with memory B cells and was lost on germinal center B cells. Expression of PD-1 ligands (PD-Ls) was induced by TLR9 activation. Finally, we showed that PD-1 was recruited to the B-cell receptor upon triggering. We determined that during TLR9 activation, blockade of PD-1/PD-Ls pathways indeed increased B-cell activation, proliferation and the production of inflammatory cytokines. Altogether, our results show, that, as reported in T cells, PD-1/PD-Ls complexes acted as inhibitors of the B-cell activation cascade and highlight the importance of devising future therapies able to modulate lymphocyte activation through the targeting of the PD-1/PD-Ls pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23087177     DOI: 10.1093/intimm/dxs098

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  124 in total

1.  Hepatic Stellate Cells Directly Inhibit B Cells via Programmed Death-Ligand 1.

Authors:  Yan Li; Lina Lu; Shiguang Qian; John J Fung; Feng Lin
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

Review 2.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

3.  Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC).

Authors:  Erika Moravcikova; E Michael Meyer; Mirko Corselli; Vera S Donnenberg; Albert D Donnenberg
Journal:  Cytometry A       Date:  2018-09-13       Impact factor: 4.355

Review 4.  Heterogeneity of Memory Marginal Zone B Cells.

Authors:  Jacobus Hendricks; Nicolaas A Bos; Frans G M Kroese
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

5.  High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Changhee Park; Dohee Kwon; Jeemin Yim; Seung Geun Song; Chan-Young Ock; Young A Kim; Sung Hye Park; Tae Min Kim; Yoon Kyung Jeon
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

6.  Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Authors:  Mari Aso; Yukihiro Toi; Jun Sugisaka; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Takahiro Ogasawara; Kyoji Tsurumi; Kana Ono; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Yosuke Kawashima; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda; Shunichi Sugawara
Journal:  Oncologist       Date:  2019-11-07

Review 7.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

Review 8.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

Review 9.  PD-1 as an immune modulatory receptor.

Authors:  Sheng Yao; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

10.  Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.

Authors:  Ann J Ligocki; Joseph R Brown; Jerry Y Niederkorn
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.